Сравнение
AOD-9604 vs. CJC-1295
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Рост
Рост
Номер CAS
221231-10-3
нет данных
Молекулярная масса
1815.09 g/mol
3647.3 g/mol
Период полувыведения
0.4 h
144 h
Последовательность
Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-PheYADAIFTNSYRKVLGQLSARKLLQDIMSR-DACМеханизм действия
AOD-9604
AOD-9604 corresponds to the C-terminal fragment 176-191 of human growth hormone with an additional N-terminal tyrosine. In animal models, lipolytic effects without GH-typical adverse events (insulin resistance, IGF-1 rise) were reported. In humans, these preclinical findings did not translate into clinically relevant weight reduction in the four phase-2 obesity trials. The exact human mechanism of action is unclear; the GH receptor is not classically activated by the fragment.
CJC-1295
Synthetic analogue of growth-hormone-releasing hormone (GHRH), modified for extended half-life via a Drug Affinity Complex (DAC) binding to albumin. Acts on the pituitary GHRH receptor and stimulates endogenous growth-hormone release.
Доказательная база
Наивысшая доказательность
РКИ на людях
Исследование на людях
Исследования
3
4
из них на людях
2
3
Зафиксированные эффекты
3
3
Открытые противоречия
1
1
Задокументированные нежелательные явления
1
3
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between AOD-9604 and CJC-1295?
- AOD-9604 is classified as "Рост", while CJC-1295 is classified as "Рост". AOD-9604: Synthetic 16-amino-acid peptide corresponding to the C-terminal fragment of human growth hormone (hGH 176-191). Originally developed by Metabolic Pharmaceuticals as an oral obesity therapy; all phase-2 trials missed the primary endpoint. No marketing approval. The Australian TGA Schedule 4 classification is often misunderstood. CJC-1295: Long-acting synthetic GHRH analogue modified for albumin binding (DAC). Stimulates endogenous growth-hormone release. Pharmacodynamic effect established in small human studies; clinical endpoint trials are missing. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, AOD-9604 or CJC-1295?
- The highest available evidence level is "РКИ на людях" for AOD-9604 and "Исследование на людях" for CJC-1295. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of AOD-9604 and CJC-1295 in Germany and the United States?
- Германия: AOD-9604 — Не одобрено, CJC-1295 — Не одобрено. США: AOD-9604 — Не одобрено, CJC-1295 — Только для исследований. These are factual summaries with source and review date on the individual pages.